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INTRODUCTION 
kcw~arugB: 
Mccbanisms of Action and Early 
Clinical Experience 
New immunosuppressive drugs with distinct and diverse modes of 
action are currently subjects of intense interest both in basic 
cell science and in the field of organ transplantation. They 
excite immunologists and molecular biologists interested in using 
these agents as probes to study the regulation of lymphocyte 
activation and growth. They also represent important developments 
both in the pharmaceutical industry and to clinicians interested in 
their prospective therapeutic applications. When viewed over a 
40-year perspective (1950-1990), the introduction of a new 
immunosuppressive agent into widespread clinical use for the 
prevention or control of organ graft rejection has been an 
infrequent event. Significantly, the immunosuppressive drugs used 
traditionally to suppress allograft rejection have been by-products 
of the development of anti-cancer (anti-proliferative) agents (eg. 
azathioprine) or anti-inflammatory agents (such as 
corticosteroids). The fortuitous discovery of the fungal product 
cyclosporin A (CsA) , an immunosuppressant wi th a selecti ve 
inhibitory action on T lymphocyte activation and proliferation, was 
a result of the screening of natural products for antibiotic 
activities. Only very recently, with the advent of FK 506 (a drug 
with a similar action to CsA) has an immunosuppressant been 
introduced which embodies the results of a deliberate search for 
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new, selective anti-lymphocytic agents with acceptable efficacy and 
toxicity profiles. 
The introduction in 1983 of CsA into widespread clinical 
practice for the prophylaxis of organ allograft rejection was 
followed by worldwide improvement in the results of organ 
transplantation. This set the scene for the introduction of newer, 
candidate immunosuppressive drugs offering a combination of 
specificity of action and comparative safety. The potential, 
additional applications of new drugs in the treatment of various 
non-transplant disorders, as evidenced for example, by the efficacy 
of CsA in psoriasis and certain other autoimmune diseases, has 
provided additional incentives within the pharmaceutical industry 
for the development of new immunosuppressive agents. 
Al though our knowledge of key molecular events underlying 
immune cell activation has advanced enormously in recent years, we 
still stand well short of a complete understanding of the sequence 
of events between antigen recognition, lymphocyte activation and 
cell proliferation. The most recent developments concerning the 
actions of new immunosuppressive drugs have however, shed light on 
several biochemical events crucial for immune function. Further 
understanding of these fundamental processes may a.ssist in future 
drug design. The new immunosuppressive drugs featured in this 
chapter represent a range of molecules which act at distinct sites 
in lymphocyte activation and proliferation (Table 1). Thus FK 506 
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inhibits cytokine gene expression, Rapamycin (Rapa) blocks the 
actions of cytokines but not cytokine production, mycophenolic acid 
(the active moiety of RS61443) and brequinar inhibit DNA synthesis, 
whilst deoxyspergualin (DSG) interferes with cell maturation. The 
purpose of this chapter is to review the modes of action and 
immunosuppressive properties of these new agents and to provide an 
up-to-date account of early clinical experience with each agent, 
where that is possible. 
INHIBITION OF CYTOKINE SYNTHESIS 
The hallmark of CsA and the principal factor accounting for 
its prominence as first choice conventional agent for the control 
of graft rejection is its capacity to inhibit selectively, cytokine 
gene expression in CD4+ T helper (TH) lymphocytes. This property 
is shared by the new drug FK 506. 
FK 506 
The macrolide antibiotic FK 506 (C44H69NO'2H20;mw822D) is a 
fermentation product of the fungus Streptomyces tsukubaensis. It 
was identified in 1982-83 by the Fujisawa Pharmaceutical Co. Ltd., 
in Osaka, Japan during routine screening of natural products for 
specific inhibitory effects on mixed lymphocyte reactions (MLR). 
Although FK 506 is totally distinct in structure (Fig. 1) from CsA, 
the two drugs have a remarkably similar molecular action; FK 506 
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is, however, ten- to one hundred- fold more potent. The recently 
published Proceedings of the First International Congress on FK 
5061 provide a comprehensive review of the molecular action, 
pharmacokinetics , immunosuppressive acti vi ties and toxicity of this 
powerful new immunosuppressant. 
THE MOLECULAR ACTION OF FK 506 
Like CsA, FK 506 acts primarily but not exclusively on 
T cells. + It blocks CD4 T helper (TH) lymphocyte activation and 
cytokine production with consequent inhibitory effects on other 
T and non-T cell components of the immune system. It inhibits 
T lymphocyte activation mediated by the T-cell receptor (TCR)-CD3 
complex and also via the cell surface molecule, CD2. 2 Induction of 
T-cell proliferation, IL-2 production and apoptosis (programmed 
cell death) are all sensitive to both FK 506 and CsA. When 
administered within one hour (and up to 6 hours) of the activa.tion 
stimulus, FK 506 is very effective in suppressing 
alloantigen-induced lymphocyte proliferation in vitro, at 
concentrations lOO-fold lower tha.n effective concentrations of CsA 
(Table 2). FK 506 also inhibits the generation of cytotoxic and 
suppressor T cells in human MLR, but does not affect antigen 
recognition by cytotoxic T cells, or the mechanism by which target 
cells are destroyed. 
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There is little evidence that of FK 506 directly affects the 
functions of accessory cells. Recently, however, Keicho etal3 
found that FK 506 partially inhibited IL-la release from phorbol 
myristate acetate (PMA)-stimulated macrophage-like U937 cells and 
from lipopolysaccharide (LPS) activated human monocytes. Earlier, 
4 Woo etal showed that concentrations of FK 506 which strongly 
inhibited antigen (purified protein derivative; PPD)-induced human 
T cell proliferation had little effect on antigen processing or 
presentation by human blood monocytes. Functions of other 
leukocytes, however, are affected by FK 506, although this may 
depend on the nature of the stimulus. Thus, FK 506 (like CsA) 
selectively inhibits calcium-dependent signalling pathways in 
murine B cells activated using anti-IgM or low dose anti-IgM plus 
IL_4. 5,6 Interestingly, both FK 506 and CsA inhibit proinflammatory 
mediator release from human basophils and rat mast cells, 7,8 as well 
as transcription of several cytokine genes, including IL-3 and 
IL-5. These actions may contribute to some of the drugs' 
therapeutic effects in graft rejection. 
In T-cells, FK 506 disrupts an unknown step in the 
transmission of signals from the cell membrane TCR to genes that 
coordinate the immune response. The drug acts at a step distal to 
cell membrane receptors and second messengers but proximal to 
transcriptional activation of early genes. Experiments designed to 
ascertain the influence of FK 506 on very early events prior to 
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gene transcription following binding of antigen to the TCR, have 
shown that the drug does not affect Ca++ mobilization, 
phosphatidylinositol turnover, activation of tyrosine kinases or 
phosphatase or the activation of serine/threonine kinases. Both FK 
506 and CsA, however, strongly and specifically inhibit expression 
of early T cell activation genes9 encoding IL-2 - the main growth 
factor for T cells, IL-3, IL-4, IFN-y, GM-CSF and c-myc. Recently, 
two subsets of murine CD4+ T cells (TH1 and TH2 ) have been identified 
on the basis of their cytokine secretion and functional profiles1o 
and there is growing evidence that such functional subsets also 
exist in man. TH1 cells produce IL-2, IFN-y, and TNFB, whereas TH2 
cells secrete IL-4, IL-5, and IL-10, but not IL-2 or IFN-y. There 
is evidence that, in vitro, FK 506 may spare IL-10 (cytokine 
synthesis inhibitory factor) gene transcription by cloned murine TH2 
cells, whilst suppressing concomitant IL-4 mRNA production. 11 Thus, 
differential interference with T cell cytokine gene expression and 
crossregulation of TH1 cell (IL-2 and IFN-y production) may be 
important mechanisms whereby FK 506 inhibits immune cell activation 
and maintains immunosuppression. 
Insight into the molecular action of FK 506 and CsA has come 
from studies of their specific, intracellular cytosolic receptors 
or "immunophilins," FK 506 binding protein (FKBP) and 
cyclophilin, respectively. 12 FKBP-12 and cyclophilin A are the 
predominant members of the FKBP and cyclophilin families of 
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"immunophilins. " Both FKBP and cyclophilin are peptidyl-prolyl 
cis-trans isomerases (PPIases) which catalyze the slow cis-trans 
isomerization of ala-pro bonds in oligopeptides and accelerate 
slow, rate-limiting steps in the folding of several proteins. 13 
Although binding of the drug by its respective immunophilin 
inhibits isomerase activity, recent results indicate that 
inhibition of isomerase activity is not the relevant effect of the 
immunosuppressants. It now appears that FK 506 and CsA function as 
prodrugs and that their immunosuppressive effects result from the 
formation of active complexes between the drug and its respective 
isomerase. These complexes interfere with signal transduction 
within the cell. Recently, Schreiber and his colleagues have shown 
that the complexes of FK 506 and FKBP and of CsA and cyclophilin 
bind specifically to three polypeptides, - calmodulin, and the two 
subunits of calcineurin (a ca++-activated, serine-threonine protein 
14 phosphatase). In each case, FK 506 or CsA promotes the 
interaction of the normally non-interacting immunophilin and 
calcineurin (Fig. 2). The drug-immunophilin complexes block the 
Ca++-activated phosphatase activity of calcineurin, which appears 
14 to be the target of these complexes. In contrast, neither FK 506, 
CsA, FKBP, nor cyclophilin alone inhibits the phosphatase activity 
f th t · I' . 14 o au en lC ca Clneurln. 
A second key observation reported by Crabtree and colleagues 
is that the drug-immunophilin complexes block ++ Ca -dependent 
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assembly of a functional gene transcription activator (NF-AT) by 
inhibiting translocation of the pre-existing component of NF-AT 
15 from the cytoplasm to the nucleus. The nuclear component of NF-AT 
is transcriptionally inactive in all cells other than activated 
T lymphocytes and is induced by signals from the TCR. Its 
appearance is not blocked by FK 506 or CsA. Current thinking is 
that FK 506 and CsA block dephosphorylation by calcineurin of the 
cytoplasmic component of NF-AT which is required for its 
translocation to the nucleus. In the absence of both nuclear and 
cytoplasmic components, binding of NF-AT to DNA and transcriptional 
activation of the IL-2 gene and other genes are suppressed 
(Fig. 3). Whilst transcription directed by NF-AT is blocked in 
T cells treated with FK 506 or CsA, little or no effect is observed 
on other transcription factors, such as NF-KB or AP_l. 15 
EFFECTS OF FK 506 ON IMMUNE RESPONSES 
Kino and colleagues first showed that treatment of mice with FK 506 
suppressed the production of antibody plaque-forming (B) cells 
against sheep red blood cells (SRBC), the generation of 
delayed-type hypersensitivity (DTH) responses against methylated 
bovine serum albumin and the development of graft-vs-host 
t . 16 reac l.ons. Short courses of FK 506 also inhibit DTH responses to 
SRBC in mice 16 and suppress the production of serum anti -SRBC 
17 
antibody and anti-MHC class I alloantibody in rats. 
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The immunosuppressive action of FK 506 however, is not fully 
understood and has not been studied extensively. Its presumed 
mechanism of action in vivo is deduced from results of in vitro 
experiments. A possible role of suppressor cells in FK S06-treated 
animals has been implied in a limited number of studies. Thus, 
flow cytometric analyses of lymphocytes of rats treated with a 
short course of FK 506 beginning on the day of immunization 
revealed a transient increase in splenic CDS+ cells, with a 
• + + 18 
concomi tant decrease 1n CD4 : CDS ratios. Interestingly, a role 
for suppressor cells in FK S06-treated animals was further 
implicated by the transfer of unresponsiveness using spleen cells 
from FK 506 treated, long-term allograft survivors to naive 
. . t 19 rec1p1en s, and by the dependence on the spleen for the 
immunosuppressi ve properties of FK 506 in mice. 20 On the other 
hand, Yoshimura etal,21 demonstrated that FK 506 prevented the 
development of suppressor cells in vitro. Thus the role of 
suppressor cells in inducing immunosuppression in FK S06-treated 
animals is unresolved. There is, however, Ii ttle doubt that 
immunosuppression in vivo is a direct result of inhibition of CD4+ 
helper T cells. FK 506 inhibits T cell maturation in mice, as 
• •• + - ... + 
eV1denced by reduct10ns 1n both CD4 CDS and CD4 CDS thymocytes in 
normal animals22 and by decreases in mature CD4 + cells in the thymus 
and peripheral lymphoid tissue following syngeneic bone marrow 
transplantation. 23 Flow cytometric analyses have revealed that, in 
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rats, the increase in number of circulating, activated (IL-2R+) CD4+ 
lymphocytes during a SRBC-induced immune response is reduced 
, 'f' tl 24 sl.gnl. l.can y. 
FK 506 AND EXPERIMENTAL ORGAN TRANSPLANTATION 
RODENTS 
In rats, long-term heterotopic cardiac allograft survival can 
be achieved by treatment with FK 506 at 0.32mg/kg, i.m. or 
, , b' t' 19,25 1. Omg /kg , p.o. l.n the F3 4 4 to WKA stral.n com l.na 1. on , or 
1.28mg/kg Lm. in the ACI (RT18 ) to Lewis (RT1l) combination. 26 
Using a different strain combination, DA (RT18 ) to PVG (RT1 u) , 
however, Lim etal27 found that long-term graft survival was not 
observed and median survival time (MST) fell between 22 to 30 days 
postoperatively. 
Using the ACI to Lewis combination, it was further 
demonstrated that a temporary, donor-specific unresponsiveness was 
developed in these long-term heart graft survival recipients; a 
graft from a third party donor was readily rej ected, while a 
second, homologous graft26,28 had prolonged survival without any 
further administration of FK 506. 26,28 The effective administration 
of FK 506 in preventing cardiac allograft rejection seems to be 
schedule-dependent as there is a shorter MST following reduction of 
treatment frequency per k 20,26,28 wee • In addition, maximum 
prolongation of cardiac allograft survival was reported when 
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treatment was given from days 4 to 6 postoperatively in the ACI to 
Lewis strain combination,26 at which time signs of cardiac graft 
rejection begin to occur. 
FK 506 is also effective in prolonging rodent skin, liver 
islet, small intestine and limb allografts and in the prevention or 
reversal of graft-versus-host disease following bone marrow 
transplantation. 
DOGS 
As with studies in the rat, FK 506 was found to be effective 
in controlling allograft rejection in dogs. 29,30 Its side effects in 
dogs, however, including anorexia and vasculitis caused 
31 32 
considerable concern.' The vascular lesions were shown to be 
relatively species-specific and not strongly associated, if at all, 
with FK 506. 33 ,34 At 1.0 mg/kg, p.o., and 0.16 mg/kg, Lm., FK 506 
induced long-term renal graft survival with healthy functioning 
31 grafts. Other groups however, have reported a less significant 
improvement. 29,30,33,34,35,36 Combinations of suboptimal, ineffective 
doses of FK 506 and CsA resulted in significant prolongation of 
renal allograft survival,29,34,37 with reduction in the incidence of 
anorexia associated with FK 506 and the toxicity attributed to 
CSA. 29,34,37 withdrawal of FK 506 usually resulted in the 
f ' t' 34 reoccurrence 0 reJec 10n. FK 506 rescue treatment could reverse 
34 36 80% of ongoing rejection in renal allografts. ' 
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Apart from the prolonging renal allograft survival, a short 
. 343638 39 
course of FK 506 treatment can also prolong l1ver " pancreas 
and pancreaticoduodenal40 graft survival in dogs at dosages similar 
to those that prolong renal allograft survival. 
NON-HUMAN PRIMATES 
Renal transplants performed on cynomolgus monkeys34 and 
baboons34,3S,41,42 demonstrated that FK 506 was effecti ve in graft 
prolongation. Compared to the doses used to inhibit rejection in 
rats and dogs, a higher dose of FK 506, (12-18 mg/kg/d, p.o.), is 
necessary to achieve renal graft prolongation in baboons. 41 This may 
be due to the difference in sensitivity to FK 506 of lymphocytes 
from different species, since MLR reactivity of baboon lymphocytes 
appears to be more resistant to the effect of FK 506. 42,43 Induction 
of tolerance is not seen with respect to renal grafts, as 
termination of FK 506 treatment leads to reoccurrence of 
. t' 36,41 reJec 10n. However, a 3-day course of treatment with FK 506 
(1 to 2 mg/kg) can effectively overcome the rejection. 36,41,44 
INHIBITION OF CYTOKINE ACTION 
RAPAMYCIN (RAPA) 
The macrolide antibiotic Rapa (Cs1H79N03; mn 914. 2D) (Fig 1) is 
a fermentation product of the soil fungus Streptomyces 
hygroscopicus isolated by Ayerst Research Laboratories, Montreal in 
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1975. Its characteristics, including the capacity to inhibit 
growth of Candida albicans, were first described by Seghal etal in 
1975. 45 ,46 Interest in the powerful T-cell inhibitory properties of 
Rapa was rekindled in the late 1980s, following accounts of the 
immunosuppressive efficacy and safety of the structurally-related 
macrolide FK 506 in experimental and clinical organ 
transplantation. At the same time, Rapa, like FK 506, was 
identified as an important new investigational tool for the 
analysis of molecular events underlying signal transduction in 
T lymphocytes. The mode of action of Rapa, its immunosuppressive 
properties and its effects on organ allograft survival have been 
• • 47-50 tOP1CS of several recent reV1ews. 
THE MOLECULAR ACTION OF RAPA 
Rapa is a more powerful inhibitor of T lymphocyte 
proliferation than CsA. It inhibits murine and human T and B cell 
activation by a variety of pathways, including those insensitive to 
FK 506 or CsA, e.g. IL-2-mediated proliferation of IL-2 dependent 
T-cell lines, activation of human T-cells by phorbol ester (PMA) 
and anti-CD28 (Table 3) .51,52 Rapa also inhibits activation of murine 
or human B cells by lipopolysaccharide (LPS) 51 or pokeweed mitogen, 53 
respectively. It binds to the same cytosolic receptor (FKBP) as FK 
506, but not to cyclophilin. 12 In contrast to FK 506 and CsA, Rapa 
affects both TCR/CD3 and protein kinase C (PKC) activation pathways 
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within T_cells. 51 ,52 Moreover, delay in the addition of Rapa to 
cultures of T cells for up to 24 hr does not prevent its inhibitory 
effect on cell proliferation. This contrasts with the effects of 
FK 506 and CsA, which exhibit no suppressive activity when added 
more than 3-6 hours after the start of cultures, suggesting that 
Rapa principally affects later events in T cell activation. It is 
9 
also consistent with work by Tocci eta!. who showed that, in 
contrast to FK 506, which blocked mRNA expression for the early 
activation genes IL-2, IL-3, IL-4, IFN-y, TNFa, GM-CSF and c-myc, 
Rapa increased expression of these genes by approximately two-fold. 
Also, in contrast to FK 506, IL-2R expression was not inhibited by 
Rapa. Scatchard analysis of the interaction between radiolabeled, 
recombinant IL-2 (r125I_IL_2) and interleukin-2 receptor (IL-2R) 
shows that Rapa does not affect either the avidity or number of 
b ' d' 't 54 IL-2R 1n 1ng Sl es. Although Rapa does not interfere with 
radioligand binding, it may retard the intracellular incorporation 
1~ ~ 
of r I-IL-2/IL-2R complexes. The sites of action of FK 506 and 
Rapa are depicted in Fig. 4. Rapa appears to inhibit cell cycle 
't ' t ' 53,55 t k' 'd d 1 ' f t' progress10n a some p01n 1n G1. Cy 0 1ne-1n uce pro 1 era lon 
of lymphoid cell lines has been used as a model for distinguishing 
the modes of action of FK 506 and Rapa. Rapa inhibits not only 
IL-2- but also IL-4-induced proliferation of CTLL and D10.G4 cell 
I , 52 lnes. Growth of an IL-6-dependent line (MH60.BSF-2) is also 
inhibi ted by Rapa. 56 The mechanisms whereby Rapa causes these 
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inhibitory effects are uncertain and remain to be elucidated. 
Despite its structural similarity to FK 506 and its binding to and 
inhibition of FKBP, Rapa interferes with a distinct set of 
Ca ++ - independent signalling pathways, including the pathway 
emanating from the IL-2R in activated T cells. Complexes of 
FKBP-Rapa fail to bind and inhibit calcineurin phosphatase 
activity14 (Fig. 2) and the target of these complexes remains to be 
defined. Rapa does not block translocation of the cytoplasmic 
component of NF-AT to the nucleus after T cell activation. This is 
consistent with its failure to block NF-AT binding activity and 
NF-AT directed transcription. 57 
RECIPROCAL ANTAGONISM BETWEEN RAPA AND FK 506 IN VITRO 
FK 506, but not Rapa, inhibits T cell activation initiated via 
the TCR. Rapa on the other hand, inhibits IL-2-induced T cell 
proliferation, whereas FK 506 does not. These two distinct signal 
transmission pathways are blocked by complexes formed between FKBP 
and either FK 506 or Rapa. The dissociation constant of Rapa to 
FKBP and of FK 506 to FKBP are quite similar. An excess of Rapa, 
however, is required to reverse FK 506-induced inhibition of 
transcriptional activation of NF-AT, IL-2 mRNA induction, IL-2 
production or apoptosis. 52,58 Similarly, an excess of FK 506 is 
needed to revert Rapa-mediated inhibition of IL-2-induced T cell 
proliferation. Neither FKBP binding nor inhibition of the rotamase 
15 
InummoIogy ofRcnal TraDllplutalion NewIIII1DIOOIUppreuive Druga: 
Edward Arnold PubIilberB Mechanisma of Actioa and Early 
CIinical ExperieDce 
activity of FKBP alone (both FK 506 and Rapa inhibit rotamase 
activity) is sufficient to explain the action of these drugs. 
These observations demonstrate that FK 506 and Rapa antagonize each 
other's biological activity and physically interact with a common 
receptor site. CsA on the other hand, acts at an intracellular 
site distinct from the target of FK 506 or Rapa. 
SYNERGY BETWEEN RAPA AND CsA AND ANTAGONISM BETWEEN 
FK 506 AND CsA IN VITRO 
Kahan and his colleagues have reported mutually synergistic 
interactions between Rapa and CsA both in vitro53 ,56 and in vivo (see 
below). Rapa augments the inhibitory effects of CsA on human PBL 
activation by PHA, anti-CD3 monoclonal antibody, and MLR. Rapa 
also enhances the capacity of CsA to suppress cytotoxic cell 
generation and precursor frequency during alloactivation in vitro. 
Moreover, CsA potentiates the inhibitory effects of Rapa on 
proliferation of IL-2 and IL-6-dependent cell lines. 56 
In contrast, the same group has observed antagonism between low 
doses of FK 506 and CsA, using the same experimental in vitro 
systems and in the in vivo Buffalo~wistar-curth cardiac allograft 
model. 59 
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Rapa has been tested in a variety of experimental 
transplantation models and has been shown to suppress acute 
rejection of kidney, heart, skin and small bowel allografts in 
rodents, pigs, dogs or primates (reviewed). 48 Rapa in a more potent 
inhibitor than CsA of non-vascularized foetal heart allograft 
survival in mice EBAiB/~CPe;e-Od~e-OkFK A dose of 3mg/kg/day i.p. 
for 14 days prolongs graft survival from 10.6 to 146 days. 
Depending on the drug formulation, Rapa is also a potent inhibitor 
of vascularized heterotopic allograft survival in rats. Thus, 
Stepkowski et al. 60 showed that given by continuous intravenous 
infusion via osmotic pumps, Rapa (0.8mg/kg in polyethylene glycol 
for 14 days) extended cardiac graft survival (Buffalo-Wistar Furth) 
from 6.5 ± 0.5 to 80 ± 3.6 days. Similarly, a 14-day i.v. Rapa 
infusion with 0.8mg/kg prolonged the survival of Buffalo kidney 
allograft recipients from 11. 6 ± 1. 5 to 90.2 ± 62.4 days. A 
continuous course of 2 mg/kg Rapa protected kidney allografts in 
pigs61 but the same regimen was severely toxic in dogs. 
A strong synergistic effect of low doses of Rapa and CsA has 
been reported by Kahan et al,56 using the Buffalo~wistar Furth rat 
cardiac allograft model. Thus, minimally effective doses of Rapa 
(0.02 mg/kg Lv.) and CsA (2 mg/kg p.o.) when combined, allowed 
100% cardiac graft survival beyond 50 days in all graft recipients. 
Evidence has also been cited54 of combined Rapa/CsA/RS-61443 
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treatment prolonging mouse heart allograft survival from 18 to 140 
days. It has also been reported by Morris et al. 62 that combination 
of Rapa with FK506 acts synergistically to prolong mouse heart 
allograft survival. The latter data are particularly interesting 
as they are not consistent with reports that, with respect to 
T cell activation in vitro, Rapa and FK506 are reciprocal 
antagonists. This apparent discrepancy may be explained by 
differing relative concentration levels of the two drugs, since, in 
vitro, a 100-fold molar excess of one drug is required for 
exhibition of antagonism. 
INHIBITION OF DNA SYNTHESIS 
MIZORIBINE (MZB) = BREDININ 
Mizoribine (MZBi mw=259Da.) (Fig. 5) is an imidazole nucleoside 
antibiotic, isolated from the soil fungus Eupenicillium 
brefeldianum. Like mycophenolic acid (MPA) , MZB inhibits the 
activity of inosine monophosphate dehydrogenase (IMPDH) in 
mammalian cells and its growth inhibitory effects are reversed by 
guanine and guanine monophosphate. Amongst its reported effects on 
the immune system, which are in accordance with its molecular 
action, are failure to inhibit early events in T cell activation, 
including mRNA levels for c-myc, IL-2, c-myb, histone and cdc2 
k ' 63 ~naseK Cytokine (IL-2) production and cell surface IL-2R 
expression induced by alloantigens, anti-CD3 monoclonal antibodies 
18 
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MZB prevents 
lymphocyte proliferation in vitro, suppresses humoral immunity to 
both T-dependent and T-independent antigens and impairs DTH 
responses in experimental animals. MZB has been reported to 
exhibit equal potency to azathioprine but little bone marrow 
suppression or hepatotoxicity. It is therefore, like MPA, a 
candidate drug to replace azathioprine in clinical 
immunosuppressive drug therapy. MZB suppresses allograft rejection 
in rodents and dogs and exhibits strong, synergistic effects when 
combined with CsA to prolong graft survival. Because of reduced 
side effects compared with azathioprine, it has been used for some 
years in combination with CsA and steroids to suppresses renal 
transplant rejection in patients in Japan (see below). 
RS-61443 AND MYCOPHENOLIC ACID (MPA) 
The antipurine RS-61443 is a semi-synthetic derivative 
(morpholinoethylester) of mycophenolic acid (MPA) (Fig. 5), and may 
hold considerable promise as an adjunctive agent administered (in 
place of azathioprine) in combination with current, standard 
immunosuppressive drugs (CsA and corticosteroids). 64 It is a 
noncompetitive inhibitor of IMPDH, the rate controlling enzyme in 
the de novo biosynthesis of guanine nucleotides. Compared with 
resting lymphocytes, acti vated T- or B- cells exhibit marked 
increases in IMPDH acti vi ty a.nd in the production of guanine 
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nucleotides, which are essential for nucleic acid and protein 
synthesis. Inhibition of DNA synthesis by MPA causes accumulation 
of cells at the Gl-S interface of the cell cycle. MPA suppresses 
human T and B cell DNA synthesis stimulated by mitogens or 
alloantigens and inhibits antibody production both in vitro and in 
vivo. MPA also prevents generation of allospecific, cytotoxic 
T 11 65,66 ce s. 
RS-61443 is rapidly hydrolysed to produce free MPA, which is 
the active agent. It has a highly selective, antiproliferative 
effect restricted to T- and B cells. Since RS-61443 inhibits both 
T and B-cell proliferation and antibody production and since it has 
been reported to be neither nephro-, hepato, nor myelotoxic, it may 
represent a more effective and safe alternative to azathioprine for 
the control of graft rej ection. significantly, RS-61443 also 
strongly suppresses B-cell memory responses in vitro. Morris and 
his colleagues67 have shown that RS-61443 prolongs heterotopic mouse 
or heart allograft survival, including graft survival in sensitized 
rats. Short-term treatment induced a state of donor-specific 
tolerance. RS-61443 is also effective in prolonging heart 
xenograft (hamster to rat) survival, particularly when combined 
with a minimally effective dose of deoxyspergualin (DSG) (see 
below) and recipient splenectomy. In dogs, RS61443 monotherapy (40 
mg/kg/day) markedly prolongs renal allograft survival, but is 
associated with gastrointestinal toxicity. Triple therapy 
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consisting of RS-61443 (20mg/kg/day), CsA (5mg/kg/day) and 
methylprednisolone (O.lmg/kg/day) prolonged renal allograft 
survival from 8 days (untreated controls) to 122 days, without 
major side effects (including bone marrow suppression) or 
, f t' I' t' 68 ln ec 10US comp lca 10ns. Moreover, high-dose therapy with RS 
61443 reversed acute kidney allograft rejection in dogs. 69 
BREQUINAR SODIUM (BQR) 
The antimetabolite brequina.r sodium (BQR) (Fig. 5) is a novel, 
quinoline carboxylic acid analogue, with broad anti-tumour activity 
in mice. Its anti-cancer properties in man are currently under 
investigation. The mechanism of action of BQR in tumour cells is 
believed to involve inhibition of dihydroorotate dehydrogenase, an 
enzyme in de novo pyrimidine biosynthesis, resulting in depletion 
of precursors required for RNA and DNA synthesis. Recent studies 
have revealed that BQR is effective in inhibiting MLR and 
cell-mediated immunity in mice. It has also been shown to be very 
effective either alone or in combination with CsA, at 
subtherapeutic doses, in the prolongation of experimental heart, 
liver or kidney allograft survival in the rat EACf~iewFK The 
potency of BQR in experimental organ transplantation is similar to 
that of CsA. 70 Treatment of kidney or liver allograft recipients 
with BQR for 30 days was sufficient to induce indefinite survival 
of the graft. In long-term liver allograft survivors, the 
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unresponsiveness was donor-specific. with respect to preclinical 
toxicity evaluation, both the bone marrow and gut appear to be 
targets, especially in the dog. Based on these findings, BQR may 
prove a valuable new adjunctive immunosuppressive agent for 
treatment of organ graft rejection. 
INHIBITION OF CELL MATURATION 
DEOXYSPERGUALIN (DSG) 
15 deoxyspergualin (DSG) is a semi-synthetic polyamine 
(mw 496.9; C'7H37N7033HCL) (Fig. 6) with anti-tumour activity. The 
bacterium Bacillus lactosporus synthesizes a natural product, 
spergualin, which, when synthetically hydroxylated, is converted to 
DSG. It exhibits a novel spectrum of immunosuppressive acti vi ty in 
experimental animals and has been shown to be effective in 
allogeneic and xenogeneic transplantation models in non-human 
primates. In man, it is effective (either alone or in combination 
with other agents) as rescue therapy in renal transplantation (see 
below) . 
Elucidation of the mode of action of DSG in vitro has been 
slow, due largely to drug instability at neutral pH and hydrolysis 
in culture medium. It is evident, however, that DSG may have a 
predominant effect on monocyte/macrophage function, including 
inhibition of oxidative metabolism, lyosomal enzyme synthesis, IL-1 
production and cell surface expression of MHC class II (Ia) 
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antigens. Apart from influencing monocytes/macrophages, DSG also 
inhibits in vivo generation of cytotoxic T cells, either directly 
or indirectly. DSG does not affect IL-2 production. On the other 
hand, the recovery of secondary, cytotoxic T cell activity (that is 
susceptible to DSG) following addition of IFN-y suggests that 
suppression of IFN-y production may be the main effect of DSG on 
T cell populations. 
DSG suppresses Lps-stimulated B cell blastogenesis and in a 
hamster-to-rat xenograft model, antibody-mediated first-set 
xenograft rejection and hyperacute rejection. It thus appears that 
DSG may also affect B-cell activation, differentiation and 
maturation, leading to inhibition of antibody production. 
The precise biochemical action of DSG is uncertain. It is 
well-known however, that high levels of naturally occurring 
polyamines decrease levels of ornithine decarboxylase, thus 
elevating intracellular ornithine concentration which, in turn, is 
known to suppress cytotoxic T-cell differentiation, but not IL-2 
secretion. These properties of DSG and its effects on the immune 
system have been reviewed recently. 71 
In combination with rabbit antithymocyte globulin (RATG), DSG 
is super ior to treatment with either agent alone in prolonging 
hamster xenograft survival in the rat. optimal graft prolongation 
(21 days versus untreated control of 3 days) was achieved with RATG 
and DSG (2.5mg/kg/day) by continuous infusion. 72 The combination 
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of DSG (10mg/kg/day) with splenectomy performed 1 week before 
transplantation, resulted in survival of mouse heterotopic heart 
allografts for 17.8 days, compared with 4.7 days and 6.8 days 
respectively, with splenectomy or DSG alone. n 
15-DSG has been evaluated in abdominal, heterotopic cardiac 
transplantation in the cynomolgus monkey. Daily administration of 
"low-dose" DSG (2mg/kg Lm.) beginning on the morning of operation, 
did not affect either graft survival time or rejection grade, 
. (/k') d t' t . . t 74 whereas "hlgh dose" DSG 7.5mg g 1.m. cause sys emlC OX1Cl y. 
CLINICAL EXPERIENCE WITH NEW IMMUNOSUPPRESSIVE AGENTS 
As might be expected, clinical trials of these new 
immunosuppressive agents have lagged behind the laboratory studies. 
There are however, several preliminary reports concerning FK 506, 
RS-61443, MZB, and DSG, and a number of ongoing or planned studies 
of these and other agents. This section of the chapter will serve 
to summarize the current status of these drugs in clinical kidney 
transplantation. 
FK 506 
PITTSBURGH EXPERIENCE 
FK 506 was first used in clinical kidney transplantation in 
March, 1989. By the time of the first report, wh.ich included the 
patients transplanted by January, 1990, 36 cases had been done 
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under primary therapy with FK 506 and steroids. 75 The second 
report, which included cases transplanted through June, 1990, 
described 66 cases.?6 By the time of the First International 
Conference on FK 506, in August, 1991, some 240 cases were 
available for analysis.?? At this latter time, a continuous i.v. 
infusion of O.lmg/kg FK 506 per day was used until patients were on 
a solid diet, at which point an oral dose of 0.15mg/kg twice daily 
was started. The results and conclusions were similar throughout 
this period and showed a one year actuarial patient and graft 
survival of 90% and 74%, respectively. These results were 
comparable to a nearly equivalent number of patients transplanted 
within roughly the same time frame under CsA-based 
immunosuppression (Table 4). Both groups were unselected and 
reflected a relatively high percentage of patients undergoing 
retransplantation and/or having a high level of pre-formed 
antibodies. There were a few notable advantages to FK 506 
described in all of these initial reports. First, a sUbstantial 
fraction of successfully transplanted patients, between 40 and 50%, 
were able to be weaned off steroids. Second, an equally large 
number of patients were managed wi thout antihypertensi ve 
medications. Finally, the serum cholesterol levels were 
significantly lower in the FK 506 patients than in the patients on 
CsA. Within this most recent report was a subset of data on 
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patients who were randomized to receive CsA or FK 506. The results 
mirrored those of the larger group. 
In the subgroup of patients in which transplantation had been 
historically most successful, ie. living related donor 
transplantation, and in pediatric transplantation, FK 506 was 
associated with extremely good results. In the first 28 living 
related kidney transplantations under FK 506, patient and graft 
survival were 100%; over 80% of the patients who were more than 
5 months post-transplantation were off prednisone. 78 Of the first 
20 pediatric kidney transplantations under FK 506, only 1 was lost, 
to recurrent hemolytic uremic syndrome, and over 1/2 of the 
• 79 80 
children were taken off prednlsone. I steroid withdrawal may be 
particularly important for long-term growth and development in 
children. 
On the basis of these studies, which demonstrated that FK 506 
was at least comparable to CsA and was possibly better on the basis 
of secondary issues, a new randomized trial was begun comparing 
FK-506/prednisone with FK 506/azathioprine/prednisone. Although 
this study is still in progress, preliminary analysis (March 1992) 
indicates an early engraftment rate of 95%, with only 2 graft 
losses in the first 54 cases and no patient deaths. 81 While this 
study will need to be completed and an analysis performed over a 
longer time period, these preliminary data suggest that there is a 
learning curve associated with the use of FK 506 in kidney 
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transplantation. It may well be that FK 506 will, over time, prove 
to be superior to CsA. 
JAPANESE EXPERIENCE 
The other significant clinical experience to date with FK 506 
in kidney transplantation has been accumulated in a multicenter 
early Phase 2 trial in Japan. 82 The first report was on 37 cases, 
most of which were with living related donors. Although 100% 
patient and graft survival was obtained, some 30% of the patients 
were withdrawn from FK 506 because of side effects. At present, a 
second multicenter late Phase 2 trial is underway in Japan. 
Recently, a multicenter randomized trial was started in the 
united States. 
RESCUE 
The other use of FK 506 in kidney transplantation has been as 
rescue therapy in cases of rejection or proteinuria. About 70% of 
patients with unremitting acute rejection were successfully 
83 
salvaged. These patients were referred after failing under 
conventional immunosuppression and both steroid and antilymphocyte 
therapy for rejection. In the transplant-related nephrotic 
patients, over 1/2 of the patients without chronic rejection had 
reduction or elimination of their proteinuria. 84 FK 506 rescue is 
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generally unsuccessful in situations where the predominant picture 
is one of chronic rejection. 
SIDE EFFECTS 
There are three basic categories of side effects of FK 506, 
-nephrotoxicity, neurotoxicity, and diabetogenicity. 
Nephrotoxicity is comparable in degree to that seen with CsA, and 
even the histologic picture is remarkably similar. 85 As with CsA 
the nephrotoxicity is largely reversible with dosage reductionI~In 
although there may be an irreversible chronic component seen with 
long-term toxicity, again similar to the picture seen with CsA. 
Nephrotoxicity can be distinguished from rejection rather easily by 
biopsy and can often be inferred clinically when neurotoxicity and 
diabetes are also present. A major part of learning to use FK 506 
in kidney transplantation has to do with balancing nephrotoxicity 
with underdosing, and graft biopsies are often necessary. 
Neurotoxicity is manifested principally by tremors, 
paresthesias of the extremities and insomnia, although other 
86 
symptoms have been seen. The symptoms have often been used as 
markers for dosage reduction and have generally been reversible. 
Serious neurologic side effects, such as seizures or confusion, 
87 have been seen rarely. 
Diabetogenicity has been seen in about 15% of non-diabetics 
receiving FK 506 after kidney transplantation. 88 It is largely 
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reversible after reduction in FK 506 and prednisone dosage, 
although a few patients have remained chronically insulin 
dependent. 
Based on the initial clinical reports, FK 506 appears to be a 
promising new agent in kidney transplantation. While it is not 
without side effects and requires experience to use effectively, it 
has the potential for offering improved outcomes after kidney 
transplantation with less long-term morbidity. 
MIZORIBINE (BREDININ) 
Mizoribine (MZB) is an agent developed in Japan that has been 
evaluated in several clinical trials there. It has been used for 
over 10 years in clinical renal transplantation. Although initial 
studies employed it alone with steroids,89 instead of azathioprine, 
in most of the recent studies, it has been used adjunctively with 
. 90-94 
esA and prednlsone. In trials comparing MZB with azathioprine, 
better or equivalent graft survival was seen with less bone marrow 
suppression and less infection. It thus appears to be safe and 
effective as a third agent in clinical transplantation. 
As MZB levels tend to correlate inversely with creatinine 
clearance, its dosage needs to be adjusted downward in response to 
renal dysfunction. 95 
Given its efficacy and the number of years it has been used 
clinically, it is rather surprising that MZB has not yet come into 
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more widespread use. Hopefully, this will change in the next few 
years. 
RS-61443 
From the outset, RS-61443, a morpholinoethyl ester of 
mycophenolic acid, has been used adjunctively, with CsA and 
prednisone, in the treatment of renal transplant patients. There 
have been 2 trials thus far, a Phase 1 dosage trial and a rescue 
trial. Preliminary reports of both trials have been published, 69,96 
and subsequent reports are in preparation. Dosages from 100 mg/d 
to 3500 mg/d have been employed with good tolerance and safety. 
Less rejection was seen at higher doses. The rescue trial looked 
at 20 cases of refractory rejection with conventional therapy, and 
found an 80% response to RS-61443 in doses of 2,000 - 3,500 mg/d. 
No evidence of nephrotoxicity, neurotoxicity, hepatotoxicity, or 
myelotoxici ty was seen with this drug. There was one case of 
hemorrhagic gastritis, possibly related to the drug. In view of 
the relative safety and efficacy of the drug in preliminary 
studies, a multicenter randomized trial has been started, comparing 
CsA, RS-61443, and prednisone with CsA, azathioprine, and 
prednisone. 
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Oeoxyspergualin (OSG) is another immunosuppressive agent that 
has been developed and evaluated largely in Japan. It has been 
used in 2 clinical settings. As it is effective only if given 
intravenously, it has no role as a maintenance agent. Rather, it 
has been used in several studies to treat refractory rejection and 
has been shown to be effective both alone and when given with 
. 97-100 
sterolds. The response rate ranged from 75 - 87%, and was over 
90% when DSG and steroids were given together. 
On the basis of the successful rescue trials, DSG was used for 
. d t' th . b' t' . th A b d . 101-103 ln uc lon erapy, ln com lna lon Wl Cs - ase reglmens. DSG 
induction has been successful in a variety of cases, - cadaveric, 
living-related, ABO-incompatible, and highly sensitized patients. 
Although the total number of cases is small, less than 40 to date, 
excellent patient and graft survival have been reported, as well as 
less rejection and nephrotoxicity. Essentially all of this 
clinical work has been in kidney transplant recipients in Japan, 
although there is one report from Sweden of the successful use of 
DSG to rescue a rejecting liver allograftK1~ 
Side effects of DSG include reversible leukopenia; facial 
numbness or warmth, nausea, and anorexia have been noted as 
symptoms in a minority of patients, but have not been severe. 
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To date, clinical reports on either rapamycin or brequinar 
have not yet appeared in the transplantation literature, although 
there is apparently a Phase I study of rapamycin in progress. 
In addition to these new immunosuppressant drugs, there are 
several investigational agents that have not yet been evaluated 
extensively in the laboratory and have not yet been studied 
clinically. 
CONCLUSIONS 
Recently developed immunosuppressive drugs with distinct 
molecular actions, such as FK 506, rapamycin, RS61443 and brequinar 
sodium hold considerable promise for development of new, effective, 
and less toxic anti-rejection therapies. Given the rapid progress 
in understanding the molecular events underlying signal 
transduction in lymphocytes, it is likely that even more 
sophisticated drugs will be introduced which will allow further 
refinement of pharmacological immunosuppression. 
In the next several years, we should see an explosion of 
clinical trials that will undoubtedly change the face of clinical 
immunosuppression as it is practiced today. The agents described 
in this chapter will probably have major roles in these trials and 
will likely become part of the immunosuppressive armamentarium of 
the future. 
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Table 1 Modes of action of new immunosuppressive drugs 
INHIBITORS OF CYTOKINE SYNTHESIS 
CsA 
FK 506 
INHIBITOR OF CYTOKINE ACTION 
RAPAMYCIN 
INHIBITORS OF DNA SYNTHESIS 
MIZORIBINE lPURINE SYNTHESIS 
MYCOPHENOLIC ACID (RS61443) 
BREQUINAR SODIUM lPYRIMIDINE SYNTHESIS 
INHIBITOR OF CELL MATURATION 
DEOXYSPERGUALIN 
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Table 2 Comparison of the antilymphocytic activities of FK 506 and CsA in vitro 
Response suppressed Species Conc. (nMt __ _ 
FK 506 CsA 
IL-2, IL-3 and IFN-y production Mouse 0.1-0.3 3-32 
IL-2, IL-3, IL-4, GM-CSF, TNF-a 
IFN-y gene expression 
(IL-2 production) Human 0.1-0.3 5-10 
IL-2 receptor a chain; transferrin 
receptor expression Human 0.1 10 
MLR; generation of cytotoxic Mouse 0.2-0.3 24-27 
T cells Human 0.2-0.3 20 
a Concentration causing 50% inhibition 
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Table 3 Effects of CsA, FK 506 and Rapamycin on lymphocyte activation and proliferation 
CsA FK 506 Rapa 
Main binding protein cyclophilin A FKBP-12 FKBP-12 
Effective concn. J,LM nM nM 
Reversibility ++ 
, Y y 
Inhibition of IL-2 synthesis ++ ++ 
Inhibition of IL-2R expression + + 
Inhibition of responses to: 
anti-CD3 ++ ++ ++ 
TPA ++ 
TPA + anti-CD28 ++ 
LPS ++ 
IL-2 ++ 
Cell cycle stage inhibited early Go early Go late G1 
TPA = 12-Q-tetradecanoylphorbol-13-acetate 
LPS = bacterial lipopolysaccharide 
FKBP = FK 506 binding protein 
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Table 4 Actuarial one-year survival and biochemical parameters in FK 506-treated kidney 
transplant patients 
CyA FK 506 Total 
Patient survival 
All 94% 90% 92% 
Graft survival 
All 77% 74% 76% 
Cadaveric 75% 73% 74% 
Living donor 89% 100% 96% 
Creatinine 1.9Y1.7** 2.1 Y 1.2 
BUN 31.0Y 17 36.0 Y 22 
Uric Acid 7.2 Y 2.6 8.1 Y 2.4 
Cholesterol" 236 Y 59 187 Y 51 
"P< .OOOl;all others P = NS . 
.... All biochemical values are in mg/ dL. 
For further details see text and Shapiro etal77 
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